BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioSimilar

APAC's Peptide-Capacity Gamble

For most of pharmaceutical history, the hard part was finding a molecule that worked. The GLP-1 class inverted that logic. The science arrived first &mdash...

July 09, 2026 | Analysis

The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?

In Songdo and Bengaluru, the numbers finally look like the ones the region was promised a decade ago. Celltrion closed 2025 with revenue above ₩4 trillio...

July 07, 2026 | Analysis

Samsung Bioepis and ATLATL Launch Innovation Prize to Accelerate Asia-Pacific Biotech Startups

Applications Open June 25 for Early-Stage Biotech Companies Developing Next-Generation Therapeutics and Platform Technologies ATLATL Innovation Center ("A...

June 26, 2026 | News

Samsung Bioepis and Organon Expand Canadian Biosimilars Alliance with PYZCHIVA® Commercialisation Agreement

Samsung Bioepis and Organon, a global healthcare company with a deep expertise in biosimilars, announced the expansion of their development and commer...

June 23, 2026 | News

Good Enough and Cheap, or Prove It's Equivalent? Asia's Biosimilar Trust Gap

There is a number that captures Asia's biosimilar paradox in a single line. According to Samsung Bioepis's quarterly tracking of the United States market, ...

June 15, 2026 | Analysis

Chime Biologics And Daewoong Pharmaceutical Partner To Advance Global Dupilumab Biosimilar Development

VMS Group is pleased to share that our portfolio company, Chime Biologics, in which we are also the controlling shareholder, has announced a strategic...

June 09, 2026 | News

Samsung Bioepis Launches OPUVIZ Aflibercept Biosimilar Across Europe

OPUVIZ™ 40 mg/mL solution for injection in a vial, a biosimilar referencing Eylea (aflibercept), will be rolled out across Europe, starting today...

June 01, 2026 | News

Polpharma Biologics And Tuteur Sign Landmark LATAM Biosimilar Licensing Partnership

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a...

May 25, 2026 | News

Samsung Bioepis Launches First Ustekinumab Biosimilar In Japan With NIPRO

Ustekinumab BS 45 mg Syringe for S.C. Injection「NIPRO」 is now available in Japan, after its listing under the National Health Insurance (NHI) Drug ...

May 21, 2026 | News

IQVIA And Kexing Biopharm Advance Global Biosimilar Expansion Through AI Enabled Strategic Collaboration

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthc...

May 15, 2026 | News

Henlius And Organon Secure European Approval For First Pertuzumab Biosimilar POHERDY

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHE...

May 01, 2026 | News

Mabwell Secures JFDA GMP Compliance For Denosumab Biosimilars, Marking PIC S Milestone

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its wholly-owned subsidiary, T-m...

April 22, 2026 | News

Biocon Limited Launches Bosaya And Aukelso In The United States To Expand Bone Health Access

Bosaya™ and Aukelso™ (both denosumab-kyqq products) now available in the United States, following U.S. FDA approval in September 2025 with ...

April 10, 2026 | News

Yoshindo And Cytiva Strengthen Japan’s Biologics Sovereignty Through Scalable Modular Manufacturing

Strengthening Yoshindo’s domestic biosimilar manufacturing footprint Cytiva’s modular manufacturing platform to support Yoshindo wit...

March 25, 2026 | News

Stay Connected